Bank of New York Mellon
VIR icon

Bank of New York Mellon’s Vir Biotechnology VIR Stock Holding History

Bank of New York Mellon’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.08M Buy
694,374
+110,327
+19% +$1.05M ﹤0.01% 2227
2026
Q1 		$5.23M Buy
584,047
+38,490
+7% +$307K ﹤0.01% 2293
2025
Q4 		$3.29M Sell
545,557
-11,461
-2% -$68.2K ﹤0.01% 2560
2025
Q3 		$3.18M Sell
557,018
-55,452
-9% -$284K ﹤0.01% 2569
2025
Q2 		$3.09M Buy
612,470
+15,951
+3% +$85.5K ﹤0.01% 2531
2025
Q1 		$3.87M Sell
596,519
-7,548
-1% -$67.1K ﹤0.01% 2359
2024
Q4 		$4.43M Sell
604,067
-38,216
-6% -$301K ﹤0.01% 2358
2024
Q3 		$4.81M Sell
642,283
-171,005
-21% -$1.49M ﹤0.01% 2306
2024
Q2 		$7.24M Buy
813,288
+6,359
+0.8% +$61K ﹤0.01% 2135
2024
Q1 		$8.17M Buy
806,929
+86,031
+12% +$876K ﹤0.01% 2062
2023
Q4 		$7.25M Sell
720,898
-140,586
-16% -$1.28M ﹤0.01% 2175
2023
Q3 		$8.07M Buy
861,484
+24,492
+3% +$349K ﹤0.01% 2060
2023
Q2 		$20.5M Buy
836,992
+13,824
+2% +$347K ﹤0.01% 1543
2023
Q1 		$19.2M Sell
823,168
-13,232
-2% -$338K ﹤0.01% 1567
2022
Q4 		$21.2M Buy
836,400
+106,313
+15% +$2.61M ﹤0.01% 1508
2022
Q3 		$14.1M Buy
730,087
+28,094
+4% +$714K ﹤0.01% 1693
2022
Q2 		$17.9M Buy
701,993
+427,490
+156% +$9.98M ﹤0.01% 1596
2022
Q1 		$7.06M Sell
274,503
-4,381
-2% -$130K ﹤0.01% 2257
2021
Q4 		$11.7M Buy
278,884
+17,132
+7% +$671K ﹤0.01% 2022
2021
Q3 		$11.4M Buy
261,752
+21,861
+9% +$946K ﹤0.01% 2048
2021
Q2 		$11.3M Buy
239,891
+68,585
+40% +$3.12M ﹤0.01% 2063
2021
Q1 		$8.78M Sell
171,306
-9,919
-5% -$535K ﹤0.01% 2161
2020
Q4 		$4.85M Buy
181,225
+16,219
+10% +$527K ﹤0.01% 2368
2020
Q3 		$5.66M Buy
165,006
+41,176
+33% +$1.77M ﹤0.01% 2151
2020
Q2 		$5.07M Buy
123,830
+104,213
+531% +$3.5M ﹤0.01% 2200
2020
Q1 		$672K Buy
19,617
+6,674
+52% +$179K ﹤0.01% 3226
2019
Q4 		$163K Buy
+12,943
New +$173K ﹤0.01% 3958

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
SAI
Savvy Advisors Inc New York $4.71B AUM 25.36% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon's VIR Position: Q2 2026 in Review

Bank of New York Mellon increased its Vir Biotechnology (VIR) stake by 19% in Q2 2026, buying an estimated $1.05M and bringing the position to 694,374 shares worth $7.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2227.

Bank of New York Mellon first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $21.2M in Q4 2022. 107 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Bank of New York Mellon held 694,374 shares of Vir Biotechnology worth $7.08M as of Q2 2026.
  • Bank of New York Mellon bought 110,327 Vir Biotechnology shares in Q2 2026, an estimated $1.05M.
  • Vir Biotechnology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2227 holding.
  • Bank of New York Mellon first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Bank of New York Mellon's Vir Biotechnology position peaked at $21.2M in Q4 2022.
  • 107 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.